Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board

December 24, 2025—Relief Cardiovascular announced the appointment of Harry Rowland as Chairman of the Board. The private medical technology company is developing the transcatheter Relief system, which is designed to monitor and modulate cardiac preload to relieve congestion in heart failure.

According to the company, Rowland cofounded and served as Chief Executive Officer of Endotronix, which developed the Cordella pulmonary artery sensor system. Under his leadership, Endotronix advanced the technology through its pivotal study, commercial approval, and acquisition by Edwards Lifesciences in 2024.

“One of the most fundamental challenges in heart failure is controlling congestion,” commented Rowland in the press release. “Relief’s approach to drive decongestion while protecting the kidneys has the potential to address a critical need in heart failure care. I’m thrilled to support the company as it works to deliver a scalable and clinically meaningful solution for patients and clinicians battling heart failure congestion.”

Alex Cooper, Chief Executive Officer of Relief Cardiovascular, added, “Harry is a remarkable leader who guided Endotronix from napkin sketch to commercial approval and exit. His leadership experience, domain expertise, and understanding of the clinical and operational complexities of remote management make him an exceptional fit for Relief as we expand the Relief system into broader clinical evaluation. I’m excited to work alongside Harry—his guidance will accelerate our journey and strengthen our ability to deliver meaningful benefit to patients.”

As noted in the press release, Relief Cardiovascular was founded and incubated within inQB8 Medical Technologies, LLC. In January 2025, the company announced the closing of its Series A financing to support the first-in-human study of the Relief system, which commenced enrollment in September 2025.